Breast Cancer Vaccine Trial Gets Boost with New Grant
- A new grant from the Cancer Vaccine Coalition and the V Foundation will accelerate research into WOKVAC, a therapeutic vaccine aiming to prevent recurrence in HER2+ breast cancer...
- The Cancer Vaccine Coalition (CVC) and the V Foundation for Cancer Research announced a $500,000 grant to expand a Phase 2 clinical trial of WOKVAC, a therapeutic vaccine...
- WOKVAC is designed for patients with HER2-positive breast cancer, a especially aggressive subtype representing approximately 20% of all breast cancer diagnoses.
“`html
$500,000 Grant Expands promising Breast Cancer Vaccine Trial
Table of Contents
A new grant from the Cancer Vaccine Coalition and the V Foundation will accelerate research into WOKVAC, a therapeutic vaccine aiming to prevent recurrence in HER2+ breast cancer patients.
What Happened?
The Cancer Vaccine Coalition (CVC) and the V Foundation for Cancer Research announced a $500,000 grant to expand a Phase 2 clinical trial of WOKVAC, a therapeutic vaccine developed by the University of Washington School of Medicine. This is the first grant awarded through a new initiative focused on modernizing cancer treatments.
WOKVAC is designed for patients with HER2-positive breast cancer, a especially aggressive subtype representing approximately 20% of all breast cancer diagnoses. The trial, led by Dr. Will Gwin, is currently investigating the vaccine’s ability to stimulate an immune response *before* surgery, possibly priming the body to fight any remaining cancer cells.
Understanding WOKVAC and HER2+ Breast Cancer
HER2-positive breast cancer is characterized by an overproduction of the HER2 protein, which promotes cancer cell growth. While targeted therapies like trastuzumab (Herceptin) have significantly improved outcomes, recurrence remains a significant concern. Approximately 25-30% of patients with early-stage HER2+ breast cancer will experience recurrence within 10 years, even with standard treatment.
WOKVAC differs from preventative vaccines (like those for HPV or measles) by *treating* existing cancer. It’s a personalized vaccine,meaning it’s designed based on the unique genetic signature of each patient’s tumor. This approach aims to train the immune system to recognize and destroy cancer cells expressing specific HER2-related antigens.
Early data from the trial has shown WOKVAC to be safe and to elicit a strong immune response. Researchers are now seeking to expand the trial to include more participants, increasing the statistical power needed to definitively demonstrate the vaccine’s efficacy.
How the Trial Works: A Step-by-step Look
The current clinical trial (NCT03984639 on ClinicalTrials.gov) involves patients with Stage 1,2,or 3 HER2+ breast cancer who are scheduled for surgery. Here’s a breakdown of the process:
- Baseline Assessment: Patients undergo complete testing to characterize their tumor and immune system.
- Vaccination: WOKVAC is administered alongside standard chemotherapy and targeted therapies *before* surgery. The vaccine schedule typically involves multiple doses over several weeks.
- Surgery: The tumor is surgically removed.
- Post-Surgery Analysis: Researchers analyze the tumor tissue and immune response to assess the vaccine’s impact.
- Follow-up: Patients are monitored for recurrence over an extended period.
dr. Gwin explained the dual aim of the study: “We aim to maximize the immune system’s ability to fight cancer during treatment, and then to generate long-lasting immune memory